Lack of efficacy of hydroxychloroquine in largest French study to date, with control group, including 181 patients: MedRxiv

Coronavirus by Engin Akyurt via pixabay.com (open access)

The largest study to date reporting on the use of hydroxychloroquine (HCQ) for COVID-19 involved 181 patients, 84 receiving HCQ and 97 not.  The study included all patients hospitalized between March 17 and 31 at four tertiary care centers in France who required oxygen supplementation.  Treatment began within 48 hours of admission.  Patients were excluded if they had renal failure or another contraindication to HCQ, if they were already on another investigative antiviral drug, or if they already had acute respiratory distress syndrome (ARDS).  There were some other criteria of lesser importance; the interested reader is referred to the full text of the article for further information.

The results would be disappointing to [redacted].  About a quarter of the patients in both groups developed ARDS within 7 days; 20.2% of the patients in the HCQ group and 22.1% in the no-HCQ group died or went to the ICU (a non-significant difference).  Eight patients receiving HCQ had changes in their electrocardiograms (ECG’s, showing their heart’s electrical rhythms) that required stopping HCQ.

This is the largest reported study of HCQ in COVID-19 to date and it has the strength of a fairly well-matched control group from the same center.  It didn’t show any difference in results with treatment, and almost 10% of patients treated with HCQ were stopped due to side effects of irregular heart beats.